The Gross Margin of Arrowhead Pharmaceuticals, Inc. (ARWR) is
100.00%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-09-30 |
100.00%
|
| Ticker |
Name |
Value |
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
MDGL
|
Madrigal Pharmaceuticals, Inc.
|
94.14%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
46.82%
|
|
VCEL
|
Vericel Corporation
|
74.42%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
TVTX
|
Travere Therapeutics, Inc.
|
97.89%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
BBIO
|
BridgeBio Pharma, Inc.
|
95.82%
|
|
ZNTL
|
Zentalis Pharmaceuticals, Inc.
|
7775.20%
|
|
ACAD
|
Acadia Pharmaceuticals Inc.
|
91.69%
|
|
BCRX
|
BioCryst Pharmaceuticals, Inc.
|
97.82%
|
|
CBPO
|
China Biologic Products Holdings Inc
|
65.68%
|
|
NBIX
|
Neurocrine Biosciences, Inc.
|
98.18%
|
|
PTCT
|
PTC Therapeutics, Inc.
|
97.28%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
EXEL
|
Exelixis Inc
|
96.39%
|
|
HRTX
|
Heron Therapeutics Inc
|
73.31%
|
|
MORF
|
Morphic Holding Inc
|
7775.20%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
SRRK
|
Scholar Rock Holding Corporation
|
7775.20%
|
|
XNCR
|
Xencor, Inc.
|
7775.20%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
INSM
|
Insmed Incorporated
|
79.73%
|
|
NTRA
|
Natera, Inc.
|
64.75%
|
|
PGEN
|
Precigen, Inc.
|
50.20%
|
|
VIR
|
Vir Biotechnology, Inc.
|
99.96%
|
|
TWST
|
Twist Bioscience Corporation
|
50.72%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
EDIT
|
Editas Medicine, Inc.
|
7775.20%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
MGNX
|
MacroGenics Inc
|
75.91%
|
|
MYGN
|
Myriad Genetics, Inc.
|
69.93%
|
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
88.26%
|
|
ALLK
|
Allakos LLC
|
7775.20%
|
|
AMRN
|
Amarin Corporation PLC
|
56.57%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
75.62%
|